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Xeroderma pigmentosum, Cockayne syndrome, the 
xeroderma pigmentosum- Cockayne syndrome com­
plex, and trichothiodystrophy cells have defects in 
DNA repair and are associated with clinical and cellu­
lar hypersensitivity to ultraviolet radiation (UV). Fa­
milial dysplastic nevus syndrome cells have UV hyper­
mutability. Although xeroderma pigmentosum and 
dysplastic nevus syndrome have markedly increased 
cancer risk, Cockayne syndrome and trichothiodys­
trophy do not. At the molecular level, these disorders 
are associated with several dHFerent genetic defects as 
evidenced by the existence of multiple overlapping 
complementation groups. Recent progress has been 
made in identifying the chromosomal location and 
cloning the defective genes in these disorders. Using 
T he importance of DNA repair in protection against environmental insults is exemplified by xeroderma pigmentosum in which affected patients have a more than 1000 times increased frequency of ultraviolet (UV) - induced skin cancers. Xeroderma pigmento­
sum cells are hypersensitive to killing and mutagenesis by UV and 
thus xeroderma pigmentosum serves as a human paradigm of so­
matic cell mutagenesis leading to carcinogenesis. At least seven 
different genetic defects (complementation groups) lead to defec­
tive DNA excision repair in xeroderma pigmentosum and an addi­
tional form, the xeroderma pigmentosum variant (XP-V), has clini­
cal xeroderma pigmentosum with defective postreplication repair. 
In studies with plasmid vectors we have shown defective repair of 
DNA damage caused by UVC, UVB, or aflatoxin. The link of 
defective DNA repair to cancer, however, is more complex than it 
initially appeared. Patients with Cockayne syndrome (CS) have 
clinical and cellular UV hypersensitivity like xeroderma pigmento­
sum but have defective repair only of active genes and do not de­
velop skin cancer. Recently, patients with trichothiodystrophy 
(TTD) and photosensitivity have been identified whose cells have 
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plasmid shuttle vectors we have shown abnormal re­
pair and mutagenesis of DNA damaged by 254-nm 
(UVC) or 295-nm (UVB) radiation or the chemical 
carcinogen aflatoxin in cells from patients with xero­
derma pigmentosum. Although xeroderma pigmento­
sum cells are defective in repair of all photoproducts, 
Cockayne syndrome cells appear to be defective in re­
pair of cyclobutane dimers and have normal repair of 
nondimer photoproducts. DNS cells have post UV 
plasmid hypermutability. These diseases may serve as 
models for examining molecular mechanisms of car­
cinogenesis in humans. Key words: Cockayne syndrome/ 
trichothiotlystrophy /tlysplastic nevus syndrome/ complemen­
tation groups. J Invest Dermatoll0J:96 -101, 1994 
the characteristic features of xeroderma pigmentosum but the pa­
tients do not develop skin cancer. In addition, cells from patients 
with familial malignant melanoma (dysplastic nevus syndrome 
[DNS)) are also hypermutable to UV. This report (an update of [1]) 
will review these observations in greater detail and comment on the 
implications of these human studies for theories of carcinogenesis. 
XERODERMA PIGMENTOSUM 
Xeroderma pigmentosum (Table I) is a rare, recessive disorder with 
clinical sun sensitivity, extensive freckle-like lesions in sun-exposed 
skin, and an estimated 1000 times increased risk of developing skin 
cancer (basal cell carcinoma, squamous cell carcinoma, and mela­
noma) [2.3]. Skin cancer often develops under 10 years of age and 
multiple primary cancers are common. Of nearly 1000 patients 
reported worldwide approximately 20% have progressive neuro­
logic degeneration involving mental retardation and sensorineural 
deafness, which may be associated with dwarfism and immature 
sexual development [2]. The neuropathology shows primary neu­
ronal degeneratioru 
Skin or blood cells from patients with xeroderma pigmentosum 
are hypersensitive to killing by UVC. There appears to be a correla­
tio� between the degree of cellular hypersensitivity to killing in vitro 
andthe severity of neurologic abnormalities in vivo [4]. Xeroderma 
pigmentosum cells are also hypermutable to UV [5]. Clinical hy­
permutability is believed to result in somatic mutations that ulti­
mately lead to an elevated frequency of freckling and skin cancers. 
Xeroderma pigmentosum cells have defective repair (host cell reac­
tivation) ofUV-damaged viruses such as adenovirus [6] and ofUV-
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Table I. Comparison of Clinical Features and Cellular Abnormalities in Xeroderma Pigmentosum, Cockayne Syndrome, 
and Trichothiodystrophy 
Xeroderma Pigmentosum 
Without Neurologic With Neurologic Cockayne Trichothiodystrophy 
Abnormalities Abnormalities Syndrome with Photosensitivity 
Skin 
Sun sensitivity Yes Yes Yes Yes 
Freckle-like lesions Yes Yes No No 
Brittle hair with low No No No Yes 
sulfur 
Ichthyosis No No No Some patients 
Skin cancer Yes Yes No No 
Eye 
UV keratitis Yes Yes No No 
Cataract No No No Yes 
Retinopathy 
Neurologic Status 
No No Yes No 
Mental Retardation No Yes Yes Yes 
Microcephaly No Some patients Yes Some patients 
Deafness No Yes Yes Few patients 
MRI brain Normal Atrophy Demyelination Demyelination 
Somatic features 
Sexual development Normal Normal/immature Normal/immature Decreased fertility 
Dwarfism No Some patients Most patients Most patients 
Cell studies 
Post-UV cell killing Sensitive Sensitive Sensitive Sensitive 
Unscheduled DNA synthesis Reduced/ Reduced Normal Reduced 
XP variant-normal 
Complementation groups XP-C,D.E,F XP-A,B,D,G CS-A,13 XP-B,D ,G TTD-A,B XP-D 
XP-variant 
damaged plasmids [3,7 -9]. With a UV -treated non-replacing plas­
mid vector we showed defective DNA repair as demonstrated by 
reduced expression of the damaged transcriptionally active cat gene 
transfected into xeroderma pigmentosum cells [7]. In this system 
only one UV photoproduct per transcribed gene in the plasmid was 
sufficient to inactivate cat expression in the xeroderma pigmento­
sum cells. Use of a replicating shuttle vector showed that treatment 
with 254 nm [8,9] or 295 nmt UV, or by aflatoxinBI epoxide [10], 
also resulted in reduced plasmid survival and increased plasmid mu­
tations in xeroderma pigmentosum cells. The G: C -+ A: T transi­
tion was the type of mutation induced almost exclusively by 254-
nm or 295-nm UV treatment of the plasmid. This indicates that the 
major UV photoproduct, the T -T cyclobutane dimer, was not the 
major mutagenic lesion. Treatment of the plasmid with aflatoxin BI 
epoxide resulted in approximately 50% G : C -+ T : A transversions, 
the expected mutation on the basis of damage to guanine, but other 
mutations such as G: C -+ C: G transversions and G: C -+ A: T 
transition base substitutions were also formed at a frequency of 
15-20% each [10]. 
DNA excision repair in mammalian cells is a multi-step process 
that is poorly understood. Much more is known about DNA repair 
in other species [11,12]. Bacteria have a multi-enzyme complex 
(UVR ABC) involving more than four gene products working to­
gether [13,14]. Excision repair in yeast may be more closely related 
to that in mammalian cells [12]. At least 10 genes (the RAD series) 
are involved in yeast DNA repair; many of these genes have been 
cloned and their function is being investigated [15]. DNA repair in 
rodent (Chinese hamster) cells invovles at least six genes (the ERCC 
series for excision repair cross complementing) [12,16]. Several of 
these have been cloned. Some were found to correct defects in 
human cells (Table U). 
The defect in xeroderma pigmentosum is thought to involve the 
initial, endonucleolytic step of excision repair. The seven DNA 
excision repair complementation groups in xeroderma pigmento-
t Adelberg S, Parris CN, Kraemer KH: Mutagenesis by 295 nm UV-B 
radiation of a plasmid vector replicated in xeroderma pigmentosum cells 
(abstr). ] Invest Dermatol 98:658, 1992. 
sum are called A-G whereas another form (the variant) has normal 
excision repair and defective post-replication repair [3,17] (Table 
n). The complementation groups were determined on the basis of 
correction of reduced post-UVunscheduled DNA synthesis (UDS) 
in multinucleate cells formed by fusing skin fibroblasts from two 
different patients. If the patients have different DNA repair defects, 
each cell provides what the other is missing and the fused cells have 
normal repair. 
The xeroderma pigmentosum complementation groups differ in 
frequency, geographic distribution, and· clinical features. Xero­
derma pigmentosum complementation groups A, C, and D and the 
variant form together comprise approximately 90% of nearly 500 
characterized patients (Table n). The remaining 10% is composed 
of groups F, E, G, and B, each accounting for less than 20 patients. In 
Japan group A is the most common form and is frequently associated 
with early onset of severe neurologic symptoms. This group is also 
present in Egypt and Tunisia but is rare in the U.S. and Europe. 
Group B consists of only two kindreds with clinical abnormalities of 
Cockayne syndrome in addition to those of xeroderma pigmento­
sum, one in the US [17] and one in Europe [18]. This has been called 
the xeroderma pigmentosum - Cockayne syndrome complex (see 
below). In Europe and the US Group C is the most common form. 
However, this form is rarely seen in Japan. These patients are gener­
ally free of neurologic abnormalities but may have many skin 
cancers. Group D has extensive clinical diversity including patients 
with late onset of neurologic abnormalities, patients with no neuro­
logic abnormalities, patients with the xeroderma pigmentosum­
Cockayne syndrome complex, and patients with another sun sensi­
tive disorder, trichothiodystrophy without xeroderma pigmento­
sum (see below). Group E patients generally have skin disease 
without neurologic abnormalities. Group F patients are found 
almost exclusively in Japan and have mild skin disease with no 
neurologic abnormalities despite a relatively low level of un­
scheduled DNA synthesis (10-20% of normal). Group G consists 
of five patients including three patients with the xeroderma 
pigmentosum - Cockayne syndrome complex. The variant form is 
found worldwide. These patients generally are free of neurologic 
abnormalities but may have mild or severe skin disease. 
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Table n. Level of Unscheduled DNA Synthesis, Clinical Features, Patient Number, Chromosome Location, and Gene 
Cloning Status in Xeroderma Pigmentosum and Cockayne Syndrome Complementation Groups 
Clinical Features Patients 
Complementation UDS' Approximate Gene Cloned? Human/Rodent/ 
Group (% of Normal) Skin Cancer NeuroABNLb Number Locationd Yeast (Human Chromosome) 
XP-A <2% Yes Severe 159 Japan, Europe, US, Yes-XPAC/?/RADI4j 
Egypt, Tunisia (9q34) 
XP-B 3-7% Yes XP-CS' 3 US,Europe Yes-XPBCjERCC3/ 
RAD25/(2q21) 
XP-C 10-20% Yes None 91 Europe, US, Egypt, Yes-XPCC/?/ 
Japan RAD4j(3p25) 
XP-D 25-50% Yes Moderate 52 Europe, US,Japan Yes-XPDCjERCC2 
RAD3/(19qI3.2) 
Yes XP-CS 1 France 
No Yes-TTDf 6 US,Europe 
XP-E 40-50% Yes None 13 Europe, Japan No/? 
XP-F 10-20% Yes None 16 Japan, Europe No/? (15) 
XP-G <2%,25% Yes Variable 3 Europe, Japan Yes-XPGC/ERCC5/RAD2/ 
(13q32-33) 
No XP-CS 2 US,Europe 
XP variant 100% Yes None 130 Japan, Europe, US, No/? 
Egypt 
CS-A 100% No Yes ? US, Europe No/? 
CS-B 100% No Yes ? US, Europe Yes-CSBC/ERCC6/?/ 
Yes-TTDf 
(10q) 
TTDIBR 15% No 1 Europe No 
• Unscheduled DNA synthesis 
, Neurologic abnormalities classmed as severe, moderate, or none 
'Number of patients reported from references [2,3] and Dr. E. Jung (personal communication) 
l Location of xeroderma pigmentosum patients listed by relative frequency of country or area of origin of patients. 
'Xeroderma pigmentosum-Cockayne syndrome complex, see text for details. Cells from the XP-B patient who also has CS have been said to represent CS group C. By this 
classmcation the XP-CS patients in XP-D would be in CS-D and those in XP-G would be in CS-E. 
f Trichothiodystrophy; see text for details. 
In recent years the genes for xeroderma pigmentosum comple­
mentation groups A, B, C, D, and G have been cloned (Table n). 
The gene for xeroderma pigrnentosum group A (XPA) was cloned 
by Tanaka et al [19] and was found to lie on human chromosome 9 
by hybridization to a human x rodent cell panel. XPA mRNA is 
about 1000 bases long and codes for a protein of 273 amino acids. 
The DNA sequence data suggests that this protein has a putative 
zinc finger domain; thus it is presumably involved in DNA binding 
but its function has not yet been determined. Most of the Japanese 
XP-A patients showed diminished or absent XPA mRNA and a 
homozygous G -+ C transversion at a splice acceptor site of XP A 
[20]. This information has been used to detect heterozygous carriers 
of the XPA gene in Japan [20] and to develop a polymerase chain 
reaction (PCR) assay for clinical use in rapid diagnosis of patients 
with XPA [21]. Another gene that partially corrects the XP-A de­
fect was reported by Rinaldy et al [22]. The relationship between 
these two genes is not known at present. 
In collaboration with Dr. K. Tanaka we examined the ability of 
XP-A cells containing cloned XP A gene to repair UV -damaged 
plasmid vectors.; Although the parental XP-A cells showed poor 
cat expression ofuv -treated plasmid, XP-A clones containing XPA 
had increased expression. Similarly, UV-treated replicating shuttle 
vector plasmid, pSP189 [23] showed increased survival and de­
creased mutation frequency in the XP-A cells with XP A compared ' 
to the parent XP-A line. 
The gene that corrects xeroderma pigmentosum complementa­
tion group B was cloned by Weeda et al r24]. This human gene on 
chromosome 2 was originally identified as ERCC-3, a gene that 
corrects a defect in Chinese hamster ovary mutant cells in excision 
repair group 3. The ERCC-3 mRNA is 2.9 kb and codes for a 
protein of 782 amino acids that has sequence similarities to yeast 
* Levy DD, Tanaka K, Kraemer KH: Expression of a transfected DNA 
repair gene (XPAC) in xeroderma pigmentosum group A cells improves 
DNA repair and mutagenesis ofUV-treated plasmids (abstr).] Inllest Derma­
to/100:514, 1993. 
DNA helicase. This protein appears to function as part of the basal 
transcription factor TFIIH [25]. There was a C -+ A transversion at 
a splice acceptor site in one XP-B patient [24]. 
Legerski et al [26] reported on a gene with homology to the yeast 
RAD4 gene that corrects xeroderma pigmentosum complementa­
tion group C. Several different mutations were identified in the 
XP-C gene in different patients [27]. 
A human gene on chromosome 19 that corrects a defect in Chi­
nese hamster cells (ERCC2) was found to complement the defect in 
XP-D cells [28,29]. The ERCC2 mRNA is 2.4 kb and codes for a 
protein of 760 amino acids that has sequence similarities to a yeast 
DNA helicase, RAD3 [28]. 
In a study with Dr. C. Weber we examined the ability of XP-D 
cells containing cloned ERCC2 gene to repair UV-damaged plas­
mid vectors [29a]. XP-D cells containing ERCC2 had increased 
expression of UV -treated cat plasmid in comparison to the parental 
XP-D cells. Also, UV-treated replicating shuttle vector plasmid 
pSP189 showed increased survival and decreased mutation fre­
quency in the XP-D cells with ERCC2 compared to the parent 
XP-D line. 
A gene correcting XP-G cells (XPG) was recently identified as 
identical to the human gene that corrects the rodent ERCC5 defect 
.  {30]. Of interest is that this gene was also recovered' by screening a 
frog oocyte library for sequences that produce factors that bind to 
antibodies that have strong anti-La activity produced by systemic 
lupus erythematosus patients [31]. The La protein has been impli­
cated in transcription termination by RNA polymerase III. A clone 
was recovered that had sequence homology to the yeast RAD2 
DNA repair gene. The human homologue XPG was found to 
correct the defect in XP-G cells [31]. 
COCKAYNESYNDROME 
Cockayne syndrome is an autosomal recessive disease with features 
of sun sensitivity. short stature, progressive neurologic degenera­
tion, pigmentary retinal degeneration, and progressive deafness 
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(Table I). Patients have neurologic abnormalities including micro­
cephaly, mental retardation, normal pressure hydrocephalus, and 
calcification of basal ganglia visible on CT scan. The neuropathol­
ogy shows primary demyelination. Less than 300 patients have been 
reported [32,33]. Unlike xeroderma pigmentosum, Cockayne syn­
drome is not associated with cancer. 
Laboratory studies of cultured cells from Cockayne syndrome 
patients to have a similar hypersensitivity to killing by UV as found 
with xeroderma pigmentosum cells [3]. However, Cockayne syn­
drome differs from xeroderma pigmentosum in that the usual assays 
of DNA excision repair are normal. A characteristic feature of 
Cockayne syndrome cells is delayed recovery of DNA and RNA 
synthesis following UV radiation [34,35]. This assay was used to 
assess genetic heterogeneity. Three complementation groups were 
found [34,36] (Table ll). Complementation groups A and B consist 
of patients with Cockayne syndrome while complementation 
group C consists of the patients who have both xeroderma pigmen­
tosum and Cockayne syndrome in xeroderma pigmentosum com­
plementation group B. Venema et al [35] examined repair of tran­
scriptionally active genes (which are normally repaired at a faster 
rate than are inactive genes) in Cockayne syndrome cells. Venema et 
al [35] demonstrated that whereas repair of total genomic DNA is 
normal, there is defective repair of actively transcribing genes in 
cells from Cockayne syndrome. The gene correcting complementa­
tion group B of Cockayne syndrome was found to be ERCC6 [37 -
39] on chromosome 10, which also corrects the defect in hamster 
complementation group 6 (Table ll). This gene like the Escherichia 
coli gene mfd, appears to assist in transcription of damaged genes 
[14]. Thus the same gene appears to play a role both in DNA repair 
and in control of transcription. 
We found reduced expression of a transcriptionally active cat 
gene in a UV -treated plasmid transfected into Cockayne syndrome 
and xeroderma pigmentosum cells [40]. Treatment of the UV dam­
aged plasmid with the enzyme photolyase resulted in selective re­
moval of cyclobutane pyrimidine dimers leaving only non-dimer 
photoproducts. The xeroderma pigmentosum cells showed in­
creased cat expression that was still reduced below the normal level. 
In contrast, cat expression was increased to normal levels with the 
Cockayne syndrome cells transfected with the plasmid containing 
only non-dimer photoproducts. These experiments indicate that 
Cockayne syndrome cells, like xeroderma pigmentosum cells, are 
not able to repair cyclobutane dimers in DNA. However, in contrast 
to xeroderma pigmentosum cells, Cockayne syndrome cells are able 
to repair non-dimer photoproducts. Thus these human cells appear 
to repair different photoproducts differently. 
Because cancer induction is thought to be related to somatic mu­
tagenesis we examined the ability of Cockayne syndrome cells to 
introduce mutations into UV-treated DNA. With the Cockayne 
syndrome cells, as with xeroderma pigmentosum cells, survival of 
UV-treated replicating shuttle vector plasmid, pZ189, was lower 
and mutation frequency higher than with normal cells. Photoreac­
tivation of the UV -treated plasmid to remove cyclobutane dimers 
resulted in normal plasmid survival and mutation frequency with 
the Cockayne syndrome cells, but survival and mutations remained 
abnormal with the xeroderma pigmentosum cells [41]. These re­
sults link the UV cancer resistance in Cockayne syndrome to profi­
cient repair of non-dimer photoproducts in active genes. Although 
other factors may also be important, this difference between Cock­
ayne syndrome and xeroderma pigmentosum maYllay a role in 
cancer susceptibility in xeroderma pigmentosum an cancer resist­
ance in Cockayne syndrome. 
XERODERMA PIGMENTOSUM-COCKAYNE 
SYNDROME COMPLEX 
Patients with the xeroderma pigmentosum-Cockayne syndrome 
complex have clinical features of Cockayne syndrome plus skin 
abnormalities of xeroderma pigmentosum including skin cancers 
[3,17]. Recognition of this complex is based on clinical findings. 
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Cockayne syndrome patients without xeroderma pigmentosum do 
not have the marked freckling found with xeroderma pigmento­
sum. Patients with xeroderma pigmentosum and neurologic abnor­
malities (such as those with the deSanctis-Cacchione syndrome) 
also have progressive neurologic degeneration and deafness and may 
also have short stature. However, patients with the xeroderma 
pigmentosum-Cockayne syndrome complex can be distinguished 
by the presence of retinal degeneration, normal pressure hydro­
'cephalus with increased deep tendon reflexes, and calcification of 
the basal ganglia. Less than 10 of these patients have been described 
(Table ll). They differ from the usual Cockayne syndrome patient 
in having reduced unscheduled DNA synthesis. of interest is that 
these patients' cells fall into three different xeroderma pigmento­
sum complementation groups: B, D (formerly H), and G. One 
xeroderma pigmentosum - Cockayne syndrome patient in comple­
mentation group B [17] and one in group D had skin cancers; two 
older xeroderma pigmentosum - Cockayne syndrome patients in 
group B did not have skin cancer [18]. The xeroderma 
pigmentosum -Cockayne syndrome patients in complementation 
group G all had severe neurodegeneration and died in early child­
hood [42]. 
The genes for xeroderma pigmentosum complementation groups 
B, D, and G are on different human chromosomes (2,19, and 13 
respectively). Thus, this implies that defects in several different 
genes may result in the xeroderma pigmentosum-Cockayne syn­
drome complex. Identification of the molecular abnormalities in 
the group B, D, and G genes in cells from these patients should 
afford insights into whether a single gene defect can lead to the 
apparent combination of two disorders. An alternative explanation 
is that each patient has a defect in more than one gene 143]. It is 
theoretically possible that the products of the genes for comple­
mentation groups B, D, and G work in concert to form a molecular 
DNA repair complex that may also have a role in regulation of 
transcription [12]. 
TRICHOTHIODYSTROPHY 
Trichothiodystrophy (TID) or Tay syndrome patients, have ich­
thyosis, sulphur-deficient brittle hair, intellectual impairment, de­
creased fertility, and short stature, which has been given the 
eponym IBIDS. Photosensitive patients are then said to have 
PIBIDS. Cataracts are common. Trichothiodystrophy is not asso­
ciated with cancer (Table I). It appears to be autosomal recessive 
and a small number of affected families have been described in Italy 
[44,45]. 
Fibroblasts from PIBIDS patients have been found to have the 
features of hypersensitivity to killing by ultraviolet and reduced 
unscheduled DNA synthesis similar to cells from patients with xer­
oderma pigmentosum [46]. Fusion studies revealed the PIBIDS cells 
to be in xeroderma pigmentosum complementation group D or in 
two unique complementation groups (TID-A and TID-B) 
(Tables 1 and ll). Fibroblasts from most trichothiodystrophy pa­
tients without sun sensitivity had normal UV survival and normal 
unscheduled DNA synthesis; however, fibroblasts from one patient 
had normal UV survival, but 50% of normal DNA repair synthesis 
[46]. 
DYSPLASTIC NEVUS SYNDROME 
Patients with familial dysplastic nevus syndrome (DNS) do not have 
marked clinical sun sensitivity like xeroderma pigmentosum or 
Cockayne syndrome but do develop multiple clinically and histo­
logically abnormal nevi [47]. Family members with dysplastic nevi 
have a more than 100 times elevated risk of developing cutaneous 
melanoma [48]. Genes for familial DNS have been reported to be 
linked to chromosomes 1 [49] and 9 [50]. 
Cells from patients with DNS have been reported to be hyper­
sensitive to killing by UV by some laboratories but have reported 
normal post-UV survival in other laboratories. DNS cells have cel­
lular UV hypermutability [51]. We recently have confirmed the 
plasmid UV hypermutability of DNS cells with normal post-UV 
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plasmid survival [52a]. Studies of DNA excision repair and post-re­
plication repair have been normal [51]. 
RELATIONSHIP OF DEFECTIVE DNA REPAIR 
TO CANCER 
Xeroderma pigmentosum patients in complementation groups A­
G have a high incidence of skin cancer in association with cellular 
UV hypersensitivity and UV hypermutability along with defective 
DNA repair of UV damage in the genome overall. Repair of ac­
tively transcribing genes is defective in XPA but normal in XPC. 
Studies with shuttle vectors in XPA suggest that repair of cyclobu­
tane dimers and non-dimer photoproducts in the active genes is 
defective. 
Xeroderma pigmentosum variant patients have increased cancer 
frequency in association with normal or nearly normal post-UV cell 
survival and cellular UV hypermutability. DNA excision repair is 
normal but there is defective post-replication repair, a poorly under­
stood process. The combination of increased skin cancer frequency 
and cellular UV hypermutability with normal excision repair is also 
seen in familial DNS. 
Cockayne syndrome patients have a similar clinical photosensi­
tivity to xeroderma pigmentosum but do not have the marked 
freckling or increased skin cancer. Their cells have a similarly in­
creased sensitivity to killing by UV and are hypermutable. Repair of 
UV damage to DNA in the genome overall is normal, although 
there is reduced repair of actively transcribed genes. Studies with 
shuttle vectors suggest that repair of cyclobutane dimers in the 
active genes is defective whereas repair of non-dimer photoproducts 
is normal. 
Trichothiodystrophy patients, like Cockayne syndrome patients, 
have sun sensitivity, short stature, and mental retardation with de­
myelination of the brain but do not have an increased incidence of 
skin cancer. Their cells are hypersensitive to killing by UV and 
some show the XP-D type of defective DNA repair. 
There are several hypotheses to explain these diverse observations 
linking DNA repair defects to skin cancer. 
1. Defective repair of UV damage in the genome overall is the 
major factor in carcinogenesis. Although this does explain the dif­
ference between xeroderma pigmentosum and Cockayne syndrome 
it does not explain the difference between xeroderma pigmentosum 
and trichothiodystrophy. 
2. Defective repair ofuv damage in actively transcribing genes is 
the major factor in carcinogenesis. Both XP A and Cockayne syn­
drome have this defect but in Cockayne syndrome cells this is asso­
ciated with proficient repair of non-dimer photoproducts. Thus, 
proficient repair of non-dimer photoproducts may be protective 
against UV carcinogenesis. Additionally, a combination of defective 
repair of the genome overall along with defective repair of active 
genes may be crucial determinants of carcinogenesis. 
3. Specific mutations in the DNA repair genes may result in 
different clinical symptoms. Only three different mutations in the 
XPA gene have been identified in several dozen Japanese XP-A 
patients. The most common mutation is associated with severe neu­
rologic abnormalities, whereas the others have more mild disease. 
By analogy, the specific defect in the ERCC2 gene in trichothio­
dystrophy might dissociate the DNA repair deficiency from the 
increased cancer incidence. Such mutations might function to alter 
the level of a repair protein or alter its specific activity. There is 
recent evidence that DNA repair genes may also playa role in 
regulation of transcription [12,14,25]. Thus a change in one gene 
could affect many systems. 
4. An additional abnormality may be responsible for the increased 
cancer in xeroderma pigmentosum. This could be multiple effects 
of a single gene or as suggested by Lambert et al [43] co-recessive 
inheritance of several genes. We recently have found an immune 
defect in xeroderma pigmentosum patients [53]. This might be ab­
sent in trichothiodystrophy and Cockayne syndrome [45,54]. 
It is clear that these possibilities are not exhaustive or mutually 
exclusive. Studies of DNA repair have recently advanced to a more 
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molecular level with the cloning of defective genes. Determining 
the mechanisms involved should yield important insights into how 
genetics and environment interact to result in markedly different 
clinical symptoms. 
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